Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma

MLA

Mark Agulnik, et al. “Efficacy, Safety, and Immune Priming Effect of Tazemetostat in Patients with Epithelioid Sarcoma.” Journal of Clinical Oncology, vol. 38, May 2020, p. 11564. EBSCOhost, https://doi.org/10.1200/jco.2020.38.15_suppl.11564.

APA

Mark Agulnik, Olivier Mir, Victor M. Villalobos, Antoine Italiano, Jay Yang, Mrinal M. Gounder, Tom Wei-Wu Chen, Abha A. Gupta, Silvia Stacchiotti, Thierry Jahan, Palma Dileo, Gregory M. Cote, Steven Attia, Laura Sierra, Robin L. Jones, Patrick Schöffski, Shefali Agarwal, Joseph G. Pressey, Ravin Ratan, & Trupti Lingaraj. (2020). Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma. Journal of Clinical Oncology, 38, 11564. https://doi.org/10.1200/jco.2020.38.15_suppl.11564

Chicago

Mark Agulnik, Olivier Mir, Victor M. Villalobos, Antoine Italiano, Jay Yang, Mrinal M. Gounder, Tom Wei-Wu Chen, et al. 2020. “Efficacy, Safety, and Immune Priming Effect of Tazemetostat in Patients with Epithelioid Sarcoma.” Journal of Clinical Oncology 38 (May): 11564. doi:10.1200/jco.2020.38.15_suppl.11564.